Pure Global

Anti-SARS-COV-2 RBD CLIA Microparticles - Indonesia BPOM Medical Device Registration

Anti-SARS-COV-2 RBD CLIA Microparticles is a medical device registered with Indonesia's BPOM (Badan Pengawas Obat dan Makanan) under Analysis ID AKL 20303126029. The device is manufactured by AUTOBIO DIAGNOSTICS CO.,LTD from China, and is classified as Risk Class Kelas Resiko : B. The authorized representative in Indonesia is PT. GRACIA VISI PRATAMA.

This page provides comprehensive regulatory information including complete registration details, manufacturer information, authorized representative details, product classification, and related products. Pure Global AI offers free access to 67,600+ Indonesia medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.

Free Database
Powered by Pure Global AI
BPOM Registered
Risk Class Kelas Resiko : B
Anti-SARS-COV-2 RBD CLIA Microparticles
Analysis ID: AKL 20303126029

Risk Classification

Kelas Resiko : B

Product Class

Kelas : 2

Country of Origin

China

Authorized Representative

PT. GRACIA VISI PRATAMA

AR Address

Jl. Soekarno Hatta No. 8A, Kel. Tlogosari Kulon, Kec. Pedurungan, Kota Semarang

Registration Date

Jul 13, 2022

Expiry Date

Jun 02, 2024

Product Type

Serological Reagents

Respiratory viral panel multiplex nucleic acid assay

Invitro Diagnostics

Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing